美国将在2025年10月1日前对进口的品牌药品征收100%的关税,除非在美国实施,否则会危及澳大利亚负担得起的医药计划。 U.S. to impose 100% tariffs on imported branded drugs by Oct. 1, 2025, unless made in America, risking Australia’s affordable medicine program.

美国宣布从2025年10月1日起对进口品牌药品征收100%的关税,除非制造商建造美国工厂,威胁澳大利亚负担得起的医药计划。 The U.S. has announced a 100% tariff on imported branded pharmaceuticals starting October 1, 2025, unless manufacturers build U.S. plants, threatening Australia’s affordable medicine program. 这一举动有可能破坏澳大利亚依赖低成本进口的保健系统的稳定,并已经引发市场衰退,尽管一些公司和部门已经反弹。 The move risks destabilizing Australia’s healthcare system, which relies on low-cost imports, and has already triggered market declines, though some companies and sectors have rebounded. 该政策反映了更广泛的美国贸易向转折的转变,引起全球对供应链和公共卫生的关切。 The policy reflects broader U.S. trade shifts toward reshoring, raising global concerns about supply chains and public health.